Sign in
CompletedPhase 1/2

Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis

Key facts

Who runs it
PT. Prodia Stem Cell Indonesia
Where
Indonesia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
31 people enrolled
Started
3 Aug 2020
Ended
8 Dec 2024
Type of study
Interventional, 4 groups
Treatments tested
  • Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
  • Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome
  • Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
  • Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome
Record updated
25 February 2026

Who can take part

Age
55 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Patients aged 55-70 years
  • Suffering from grade 2-3 OA was identified by two observers who differed accordingly Kellgren-Lawrence research scale
  • Absence of local or general infections
  • Haematological and biochemical analysis without significant changes being made cause contraindications
  • Patients can understand the nature of the study
  • Written informed consent is given to patients

Who cannot take part

  • Articular injection of the knee by any drug during the previous 3 months
  • Participate in any clinical trial or treatment 30 days before the study
  • There are signs of infection or positive serology for HIV, hepatitis and syphilis
  • There is a history of cancer both in the family and yourself and the value of the examination tumour marker exceeds normal limits
  • There is a congenital disease that causes significant deformity of the knee can interfere with cell applications and interpret results
  • Other conditions may, according to medical criteria, not support participation in this research
  • Patients are not willing to obey the study protocol
  • Patients are subordinates or low ranking members

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to compare the efficacy of Umbilical Cord Mesenchymal Stem Cell and secretome between arthroscopy and without arthroscopy intervention in OA patients. This study has 4 arms namely Arthroscopy + Booster, Arthroscopy + Pre-conditioning, Non-Arthroscopy + Booster, Non-Arthroscopy + Pre-conditioning.

The 4 groups in the trial

  • Arthroscopy + BoosterTreatment being tested

    After arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.

    Treatment: Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome

  • Arthroscopy + Pre-ConditioningTreatment being tested

    After arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.

    Treatment: Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome

  • Non Arthroscopy + BoosterTreatment being tested

    Without arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.

    Treatment: Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome

  • Non Arthroscopy + Pre-ConditioningTreatment being tested

    Without arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.

    Treatment: Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Innovative Osteoarthritis Therapy Using Combination of Mesenchymal Stem Cell (MSC) and Conditioned Medium (CM): A Comparative Study on Arthroscopy and Non-Arthroscopy
Record updated
25 February 2026